Monopar Therapeutics 8-K

What Happened
Monopar Therapeutics (MNPR) filed an 8-K on June 26, 2026 (Regulation FD disclosure) announcing new analyses from the Phase 3 FoCus trial showing "greater neurologic and global clinical benefit" of ALXN1840 (tiomolibdate choline) versus standard of care in patients with neurologic Wilson disease. The company will present the analyses and a poster at the 12th Congress of the European Academy of Neurology (EAN), taking place June 27–30, 2026. The press release and poster are furnished as Exhibits 99.1 and 99.2 to the filing.

Key Details

• Filing date: June 26, 2026 (Form 8-K, Item 7.01 Regulation FD Disclosure).
• Drug and trial: ALXN1840 (tiomolibdate choline) — Phase 3 FoCus trial in neurologic Wilson disease.
• Presentation: Poster and analyses to be presented at EAN Congress, June 27–30, 2026.
• Exhibits: Press release (Ex. 99.1) and poster presentation (Ex. 99.2) furnished and incorporated by reference.

Why It Matters
This filing discloses new Phase 3 clinical data for Monopar’s lead program, which is directly relevant to the company’s clinical development and regulatory outlook for ALXN1840 in Wilson disease. Retail investors should note the timing (presentation at a major neurology conference) and that substantive trial analyses have been made public; these materials (press release and poster) are available as exhibits to the 8-K for review.